Citi raised the firm’s price target on Shattuck Labs (STTK) to $7 from $4 and keeps a Neutral rating on the shares. Citi also added an “upside 90-day catalyst watch” on Shattuck. The company is slated to report initial Phase 1 data for SL-325 in healthy volunteers in Q2, the analyst tells investors in a research note. Citi believes the data could highlight SL-325’s differentiation versus competing anti-TL1A antibodies.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STTK:
- Shattuck Labs price target raised to $8 from $4 at Wedbush
- Shattuck Labs transferred with Buy rating at Needham
- Buy Rating on SL-325: Differentiated DR3 Targeting in IBD Supports Attractive Risk/Reward and $14 Price Target
- Shattuck Labs reports Q4 EPS (12c), consensus (13c)
- Shattuck Labs expects available cash to fund operations into 2029